SQZ Biotech

SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

SQZ Biotech headquartered in United States, North America, operates in the Biotechnology, Life Science, Therapeutics sector. The company focuses on Biotechnology and has secured $35.9B in funding across 156 round(s). With a team of 101-250 employees, SQZ Biotech is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - SQZ Biotech, raised $15.0K. Discover more about their projects, partnerships, and impact on our platform.